Skip to main content

Home/ WSU Virology/ Group items tagged interferon

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Casey Finnerty

Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability - 0 views

jvi.asm.org/...10208.long

Dengue virus virology

shared by Casey Finnerty on 29 Nov 12 - No Cached
  • Casey Finnerty on 29 Nov 12
     
    This paper describes the development of the DENV mouse-adapted strain DS10, which can reproduce severe Dengue Fever in the mouse strain AG129. AG129 mice are doubly deficient in the receptors for alpha/beta interferon and gamma interferon.
Haram LEE

BMC Cancer | Full text | Oncolytic Targeting of Androgen-sensitive Prostate Tumor by th... - 4 views

www.biomedcentral.com/...43

vriology Oncolytic virotherapy RSV

shared by Haram LEE on 27 Sep 12 - No Cached
Trevor F liked it
  • Haram LEE on 27 Sep 12
     
    Oncolytic virotherapy for cancer treatment utilizes viruses for selective infection and death of cancer cells without any adverse effect on normal cells. We previously reported that the human respiratory syncytial virus (RSV) is a novel oncolytic virus against androgen-independent PC-3 human prostate cancer cells.
  • ...2 more comments...
  • Haram LEE on 27 Sep 12
     
    Is there any other virus can using for Oncolytic virotherapy? - Oncolytic viruses identified to date are: adenovirus, reovirus, herpes simplex virus (HSV), Newcastle disease virus (NDV), vaccinia virus, myxoma virus, influenza virus, measles virus, coxsackievirus and vesicular stomatitis virus (VSV) (Anticancer oncolytic activity of respiratory syncytial virus., http://www.ncbi.nlm.nih.gov/pubmed?term=Anti-cancer%20oncolytic%20activity%20of%20respiratory%20syncytial%20virus)
  • Haram LEE on 27 Sep 12
     
    Why also using xenograft, not only for cell-culture method? - A human prostate tumor xenograft model (30) was used to examine the oncolytic function of RSV in vivo (Figure 2). -We also investigated the efficacy of intraperitoneally (I.P) delivered RSV for causing tumor regression and determined that intraperitoneally injected RSV also rendered significant reduction in the tumor growth compared to the growth of control, medium-treated tumors (Figure 2c). The significant tumor regression by intraperitoneally delivered RSV is shown in Figure 2d. Similar results were obtained with tumors grown in the dorsal flank (Supplementary Figure S2). Therefore, the RSV-responsive restriction of tumor growth at two sites (ear and flank) demonstrates the versatility of RSV in conferring oncolysis in vivo at different anatomical regions. (Anticancer oncolytic activity of respiratory syncytial virus., http://www.ncbi.nlm.nih.gov/pubmed?term=Anti-cancer%20oncolytic%20activity%20of%20respiratory%20syncytial%20virus)
  • Haram LEE on 27 Sep 12
     
    How Oncolytic virus control the inflammation? - Oncolytic virus treatment induced at least a twofold increase or decrease in the expression of 50 genes relative to expression in the PBS-treated tumors (Supplementary Table 1, available online). Of these 50 genes, 48 displayed an increase in expression in the oncolytic virus - treated tumors compared with the controltreated tumors, suggesting that oncolytic virus treatment induced an inflammatory response - To confirm the role of the immune response in oncolytic virus - induced vascular hyperpermeability, we evaluated changes in oncolytic virus - induced vascular leakage in tumor-bearing rats that had been treated with cyclophosphamide before oncolytic virus injection. In addition to its immunosuppressive effects, cyclophosphamide blocks infl ammation and reduces viral clearance, both of which increase the propagation of oncolytic viruses, thereby enhancing therapeutic effi cacy of oncolytic viruses. (Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy, http://www.ncbi.nlm.nih.gov/pubmed?term=Effect%20of%20Tumor%20Microenvironment%20Modulation%20on%20the%20Efficacy%20of%20Oncolytic%20Virus%20Therapy)
  • Haram LEE on 27 Sep 12
Casey Finnerty

We Now Have the Cure for Hepatitis C, but Can We Afford It? - Scientific American - 13 views

www.scientificamerican.com/...patitis-c-but-can-we-afford-it

hepatitis medicine antiviral HCV

shared by Casey Finnerty on 09 Dec 14 - No Cached
  • Later this year the U.S. Food and Drug Administration is expected to approve a new pill that can cure hepatitis C
  • It will contain two drugs, one of which is already available at $1,000 per dose, or $84,000 for a complete 12-week course. The dual-drug combination will likely cost even more
  • They also determined that the virus's genes mutate very fast—a process that has generated several equally successful varieties, called genotypes, and rendered an effective vaccine impossible to create so far.
  • ...7 more annotations...
  • its genetic material, which is made up of RNA
  • After several false starts, researchers at Vertex Pharmaceuticals, in collaboration with others, developed a protease inhibitor known as telaprevir, while scientists at Schering-Plough (which merged with Merck in 2009), created one called boceprevir.
  • The medications had harsh side effects and worked only for those patients with a particular genetic variant of the virus known as genotype 1
  • What scientists had learned from their earlier research, however, was that inactivating an enzyme or protein was not enough. To stop hepatitis C, any effective drug also had to incorporate itself into the virus's genetic code, where it would need to halt the virus's ability to make new copies of its genes and thus to make new virus.
  • Michael Sofia, then at Pharmasset, solved the problems by adding two compounds known as esters to the analogue.
  • During sofosbuvir's development, they had studied other drugs that inhibited different viral proteins and that might eliminate the need for continued use of interferon and ribavirin.
  • It is this combination, mixed in a single daily pill, that industry watchers expect the FDA to approve by October 2014. It heralds a new era of curative treatment for patients with hepatitis C. Similar drugs that work equally well for all genotypes are now in the final stages of clinical development.
Casey Finnerty

Viruses as a Cure - NYTimes.com - 0 views

www.nytimes.com/...viruses-as-a-cure.html

microbiome norovirus

shared by Casey Finnerty on 20 Nov 14 - No Cached
  • When they prevented germ-free mice from making a receptor on the surface of their cells, infection with norovirus didn’t lead to an improvement in their guts.That receptor only latches onto one type of molecule. It’s called Type 1 interferon, and it’s produced by cells when they’re invaded by viruses.
1 - 9 of 9
Showing 20▼ items per page